Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147

Amanda I. Phipps, Qian D Shi, Paul John Limburg, Garth D. Nelson, Daniel J. Sargent, Frank A Sinicrope, Emily Chan, Sharlene Gill, Richard M. Goldberg, Morton Kahlenberg, Suresh Nair, Anthony F. Shields, Polly A. Newcomb, Steven Robert Alberts

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Alcohol consumption is associated with a modest increased risk of colon cancer, but its relationship with colon cancer survival has not been elucidated. Using data from a phase III randomized adjuvant trial, we assessed the association of alcohol consumption with colon cancer outcomes. Patients completed a risk factor questionnaire before randomization to FOLFOX or FOLFOX+cetuximab (N=1984). Information was collected on lifestyle factors, including smoking, physical activity and consumption of different types of alcohol. Cox models assessed the association between alcohol consumption and outcomes of disease-free survival (DFS), time-to-recurrence (TTR) and overall survival (OS), adjusting for age, sex, study arm, body mass, smoking, physical activity and performance status. No statistically significant difference in outcomes between ever and never drinkers were noted [hazard ratio (HR)DFS=0.86, HRTTR=0.87, HROS=0.86, p-values=0.11-0.17]. However, when considering alcohol type, ever consumers of red wine (n=628) had significantly better outcomes than never consumers (HRDFS=0.80, HRTTR=0.81, HROS=0.78, p-values=0.01-0.02). Favorable outcomes were confirmed in patients who consumed 1-30 glasses/month of red wine (n=601, HR=0.80-0.83, p-values=0.03-0.049); there was a suggestion of more favorable outcomes in patients who consumed >30 glasses/month of red wine (n=27, HR=0.33-0.38, p-values=0.05-0.06). Beer and liquor consumption were not associated with outcomes. Although alcohol consumption was not associated with colon cancer outcomes overall, mild to moderate red wine consumption was suggestively associated with longer OS, DFS and TTR in stage III colon cancer patients.

Original languageEnglish (US)
JournalInternational Journal of Cancer
DOIs
StateAccepted/In press - 2016

Fingerprint

Alcohol Drinking
Colonic Neoplasms
Wine
Disease-Free Survival
Neoplasms
Glass
Survival
Smoking
Exercise
Therapeutics
Recurrence
Random Allocation
Proportional Hazards Models
Life Style
Alcohols

Keywords

  • Alcohol
  • Colon cancer
  • Recurrence
  • Red wine
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. / Phipps, Amanda I.; Shi, Qian D; Limburg, Paul John; Nelson, Garth D.; Sargent, Daniel J.; Sinicrope, Frank A; Chan, Emily; Gill, Sharlene; Goldberg, Richard M.; Kahlenberg, Morton; Nair, Suresh; Shields, Anthony F.; Newcomb, Polly A.; Alberts, Steven Robert.

In: International Journal of Cancer, 2016.

Research output: Contribution to journalArticle

Phipps, Amanda I. ; Shi, Qian D ; Limburg, Paul John ; Nelson, Garth D. ; Sargent, Daniel J. ; Sinicrope, Frank A ; Chan, Emily ; Gill, Sharlene ; Goldberg, Richard M. ; Kahlenberg, Morton ; Nair, Suresh ; Shields, Anthony F. ; Newcomb, Polly A. ; Alberts, Steven Robert. / Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. In: International Journal of Cancer. 2016.
@article{431b4b56518f497a8d7cd8d7f2389194,
title = "Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147",
abstract = "Alcohol consumption is associated with a modest increased risk of colon cancer, but its relationship with colon cancer survival has not been elucidated. Using data from a phase III randomized adjuvant trial, we assessed the association of alcohol consumption with colon cancer outcomes. Patients completed a risk factor questionnaire before randomization to FOLFOX or FOLFOX+cetuximab (N=1984). Information was collected on lifestyle factors, including smoking, physical activity and consumption of different types of alcohol. Cox models assessed the association between alcohol consumption and outcomes of disease-free survival (DFS), time-to-recurrence (TTR) and overall survival (OS), adjusting for age, sex, study arm, body mass, smoking, physical activity and performance status. No statistically significant difference in outcomes between ever and never drinkers were noted [hazard ratio (HR)DFS=0.86, HRTTR=0.87, HROS=0.86, p-values=0.11-0.17]. However, when considering alcohol type, ever consumers of red wine (n=628) had significantly better outcomes than never consumers (HRDFS=0.80, HRTTR=0.81, HROS=0.78, p-values=0.01-0.02). Favorable outcomes were confirmed in patients who consumed 1-30 glasses/month of red wine (n=601, HR=0.80-0.83, p-values=0.03-0.049); there was a suggestion of more favorable outcomes in patients who consumed >30 glasses/month of red wine (n=27, HR=0.33-0.38, p-values=0.05-0.06). Beer and liquor consumption were not associated with outcomes. Although alcohol consumption was not associated with colon cancer outcomes overall, mild to moderate red wine consumption was suggestively associated with longer OS, DFS and TTR in stage III colon cancer patients.",
keywords = "Alcohol, Colon cancer, Recurrence, Red wine, Survival",
author = "Phipps, {Amanda I.} and Shi, {Qian D} and Limburg, {Paul John} and Nelson, {Garth D.} and Sargent, {Daniel J.} and Sinicrope, {Frank A} and Emily Chan and Sharlene Gill and Goldberg, {Richard M.} and Morton Kahlenberg and Suresh Nair and Shields, {Anthony F.} and Newcomb, {Polly A.} and Alberts, {Steven Robert}",
year = "2016",
doi = "10.1002/ijc.30135",
language = "English (US)",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147

AU - Phipps, Amanda I.

AU - Shi, Qian D

AU - Limburg, Paul John

AU - Nelson, Garth D.

AU - Sargent, Daniel J.

AU - Sinicrope, Frank A

AU - Chan, Emily

AU - Gill, Sharlene

AU - Goldberg, Richard M.

AU - Kahlenberg, Morton

AU - Nair, Suresh

AU - Shields, Anthony F.

AU - Newcomb, Polly A.

AU - Alberts, Steven Robert

PY - 2016

Y1 - 2016

N2 - Alcohol consumption is associated with a modest increased risk of colon cancer, but its relationship with colon cancer survival has not been elucidated. Using data from a phase III randomized adjuvant trial, we assessed the association of alcohol consumption with colon cancer outcomes. Patients completed a risk factor questionnaire before randomization to FOLFOX or FOLFOX+cetuximab (N=1984). Information was collected on lifestyle factors, including smoking, physical activity and consumption of different types of alcohol. Cox models assessed the association between alcohol consumption and outcomes of disease-free survival (DFS), time-to-recurrence (TTR) and overall survival (OS), adjusting for age, sex, study arm, body mass, smoking, physical activity and performance status. No statistically significant difference in outcomes between ever and never drinkers were noted [hazard ratio (HR)DFS=0.86, HRTTR=0.87, HROS=0.86, p-values=0.11-0.17]. However, when considering alcohol type, ever consumers of red wine (n=628) had significantly better outcomes than never consumers (HRDFS=0.80, HRTTR=0.81, HROS=0.78, p-values=0.01-0.02). Favorable outcomes were confirmed in patients who consumed 1-30 glasses/month of red wine (n=601, HR=0.80-0.83, p-values=0.03-0.049); there was a suggestion of more favorable outcomes in patients who consumed >30 glasses/month of red wine (n=27, HR=0.33-0.38, p-values=0.05-0.06). Beer and liquor consumption were not associated with outcomes. Although alcohol consumption was not associated with colon cancer outcomes overall, mild to moderate red wine consumption was suggestively associated with longer OS, DFS and TTR in stage III colon cancer patients.

AB - Alcohol consumption is associated with a modest increased risk of colon cancer, but its relationship with colon cancer survival has not been elucidated. Using data from a phase III randomized adjuvant trial, we assessed the association of alcohol consumption with colon cancer outcomes. Patients completed a risk factor questionnaire before randomization to FOLFOX or FOLFOX+cetuximab (N=1984). Information was collected on lifestyle factors, including smoking, physical activity and consumption of different types of alcohol. Cox models assessed the association between alcohol consumption and outcomes of disease-free survival (DFS), time-to-recurrence (TTR) and overall survival (OS), adjusting for age, sex, study arm, body mass, smoking, physical activity and performance status. No statistically significant difference in outcomes between ever and never drinkers were noted [hazard ratio (HR)DFS=0.86, HRTTR=0.87, HROS=0.86, p-values=0.11-0.17]. However, when considering alcohol type, ever consumers of red wine (n=628) had significantly better outcomes than never consumers (HRDFS=0.80, HRTTR=0.81, HROS=0.78, p-values=0.01-0.02). Favorable outcomes were confirmed in patients who consumed 1-30 glasses/month of red wine (n=601, HR=0.80-0.83, p-values=0.03-0.049); there was a suggestion of more favorable outcomes in patients who consumed >30 glasses/month of red wine (n=27, HR=0.33-0.38, p-values=0.05-0.06). Beer and liquor consumption were not associated with outcomes. Although alcohol consumption was not associated with colon cancer outcomes overall, mild to moderate red wine consumption was suggestively associated with longer OS, DFS and TTR in stage III colon cancer patients.

KW - Alcohol

KW - Colon cancer

KW - Recurrence

KW - Red wine

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84966459998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84966459998&partnerID=8YFLogxK

U2 - 10.1002/ijc.30135

DO - 10.1002/ijc.30135

M3 - Article

C2 - 27060850

AN - SCOPUS:84966459998

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -